Haemonetics Co. (NYSE:HAE) Forecasted to Earn Q1 2025 Earnings of $0.94 Per Share

Haemonetics Co. (NYSE:HAEFree Report) – Analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for Haemonetics in a report released on Thursday, March 28th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $0.94 per share for the quarter, up from their prior forecast of $0.93. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.08 EPS, FY2025 earnings at $4.12 EPS, Q1 2026 earnings at $1.19 EPS and FY2026 earnings at $4.77 EPS.

HAE has been the topic of a number of other research reports. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Barrington Research reissued an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a report on Tuesday, February 13th. Finally, TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th.

Read Our Latest Analysis on HAE

Haemonetics Trading Up 1.5 %

Shares of HAE stock opened at $85.35 on Friday. The business’s fifty day moving average price is $77.25 and its 200 day moving average price is $83.32. Haemonetics has a 1-year low of $70.74 and a 1-year high of $95.26. The firm has a market capitalization of $4.33 billion, a PE ratio of 34.70, a P/E/G ratio of 2.13 and a beta of 0.34. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76.

Haemonetics (NYSE:HAEGet Free Report) last announced its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The firm had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. During the same quarter in the prior year, the company posted $0.85 earnings per share. Haemonetics’s quarterly revenue was up 10.1% on a year-over-year basis.

Institutional Trading of Haemonetics

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Haemonetics by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock valued at $482,017,000 after acquiring an additional 27,146 shares during the last quarter. Kingdon Capital Management L.L.C. acquired a new stake in shares of Haemonetics during the third quarter valued at $9,952,000. Lazard Asset Management LLC boosted its stake in shares of Haemonetics by 114.2% during the third quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier’s stock valued at $3,452,000 after acquiring an additional 20,550 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Haemonetics by 1.1% during the third quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier’s stock valued at $4,753,000 after acquiring an additional 586 shares during the last quarter. Finally, Eagle Asset Management Inc. lifted its position in Haemonetics by 2.6% during the third quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier’s stock worth $24,065,000 after buying an additional 6,828 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

(Get Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

Featured Stories

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.